title: Overcoming platinum resistance in ovarian carcinoma.
abstract: BACKGROUND
  Ovarian cancer remains a deadly malignancy because most patients develop recurrent disease that is resistant to chemotherapy, including platinum. Because response rates for current treatment regimens are relatively similar and unfortunately low, no standard chemotherapy for platinum-resistant ovarian cancer exists.
  
  
  METHODS
  A systematic literature review of clinical studies published between January 2005 and March 2010 was conducted using search engines, PubMed and MEDLINE with the entry keywords 'ovarian cancer' and 'platinum resistance'. This search revealed 40 clinical trials (1793 patients).
  
  
  RESULTS
  Gemcitabine was the most common drug used in clinical trials reporting higher response rates, ≥ +1 SD of overall response rate (5 out of 8). Gemcitabine-based combination therapy showed an average response rate of 27.2% (95% CI, 22.4-32.0). Combination of gemcitabine and pegylated liposomal doxorubicin (PLD) was the most common regimen (n = 3) and was associated with possible additive effects in platinum-resistant ovarian cancer patients: response rate, gemcitabine alone 6.1%, PLD alone 19.8%, and gemcitabine with PLD 28.7% (95% CI, 20.4-37.0), respectively.
  
  
  CONCLUSIONS
  Analysis of recent clinical trials showed that gemcitabine-based combination chemotherapy was associated with the highest antitumor effects in platinum-resistant ovarian cancer patients during the study period.
authors.affiliation: University of Southern California, Norris Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 2020 Zonal Avenue, Rm 522, Los Angeles, CA 90033, USA. koji.matsuo@gmail.com
authors.forename: Koji
authors.initials: K
authors.lastname: Matsuo
authors.forename: Yvonne G
authors.initials: YG
authors.lastname: Lin
authors.forename: Lynda D
authors.initials: LD
authors.lastname: Roman
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D003841:Deoxycytidine; D000093542:Gemcitabine
references.citation: Eur J Cancer. 2009 May;45(8):1415-23
references.pmid: 19168349
references.citation: Gynecol Oncol. 2006 Apr;101(1):55-61
references.pmid: 16260029
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Med Chem. 2006 Jan;2(1):47-53
references.pmid: 16787355
references.citation: Br J Cancer. 2007 Dec 17;97(12):1618-24
references.pmid: 18000504
references.citation: Int J Gynecol Cancer. 2006 Jan-Feb;16(1):71-6
references.pmid: 16445613
references.citation: Anticancer Drugs. 2008 Jun;19(5):541-5
references.pmid: 18418221
references.citation: Gynecol Oncol. 2009 Jun;113(3):327-30
references.pmid: 19307014
references.citation: Cancer. 2006 Jul 1;107(1):83-9
references.pmid: 16736514
references.citation: Cancer. 1986 May 1;57(9):1725-30
references.pmid: 3513943
references.citation: Cancer Chemother Pharmacol. 2009 Oct;64(5):1021-7
references.pmid: 19266200
references.citation: Ann Oncol. 1998 Oct;9(10):1053-71
references.pmid: 9834817
references.citation: Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):63-6
references.pmid: 19469626
references.citation: Int J Gynecol Cancer. 2008 May-Jun;18(3):428-31
references.pmid: 17692088
references.citation: Gynecol Oncol. 2007 Mar;104(3):727-31
references.pmid: 17126894
references.citation: Clin Transl Oncol. 2008 Sep;10(9):583-6
references.pmid: 18796376
references.citation: Gynecol Oncol. 2007 Aug;106(2):354-61
references.pmid: 17499348
references.citation: Drugs. 1997;54 Suppl 4:15-21
references.pmid: 9361957
references.citation: Int J Gynecol Cancer. 2005 Jul-Aug;15(4):593-600
references.pmid: 16014111
references.citation: Am J Clin Oncol. 2008 Oct;31(5):481-7
references.pmid: 18838886
references.citation: Gynecol Oncol. 2006 Jun;101(3):423-8
references.pmid: 16325239
references.citation: Gynecol Oncol. 2007 Mar;104(3):580-5
references.pmid: 17052747
references.citation: Br J Cancer. 2009 Feb 24;100(4):601-7
references.pmid: 19190632
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2686-91
references.pmid: 19332726
references.citation: Anticancer Res. 2005 Sep-Oct;25(5):3559-64
references.pmid: 16101180
references.citation: J Clin Oncol. 2010 Jan 1;28(1):149-53
references.pmid: 19917861
references.citation: J Control Release. 2008 Oct 21;131(2):100-6
references.pmid: 18691617
references.citation: Invest New Drugs. 2005 Jan;23(1):85-9
references.pmid: 15528985
references.citation: Anticancer Res. 2005 Jul-Aug;25(4):3103-8
references.pmid: 16080573
references.citation: Anticancer Res. 2009 Jul;29(7):2851-6
references.pmid: 19596973
references.citation: Anticancer Res. 2009 Jul;29(7):2681-6
references.pmid: 19596946
references.citation: Biochem Pharmacol. 2009 Aug 15;78(4):365-73
references.pmid: 19413998
references.citation: Clin Cancer Res. 2009 Jun 1;15(11):3770-80
references.pmid: 19470734
references.citation: Int J Gynecol Cancer. 2007 Jan-Feb;17(1):159-63
references.pmid: 17291248
references.citation: Gynecol Oncol. 2004 Dec;95(3):624-31
references.pmid: 15581974
references.citation: Br J Cancer. 2009 Mar 10;100(5):707-12
references.pmid: 19223898
references.citation: J Clin Oncol. 1994 Nov;12(11):2301-8
references.pmid: 7964944
references.citation: Int J Gynecol Cancer. 2006 Jan-Feb;16(1):65-70
references.pmid: 16445612
references.citation: Med Oncol. 2007;24(1):39-43
references.pmid: 17673810
references.citation: Int J Cancer. 2009 Dec 1;125(11):2721-7
references.pmid: 19530239
references.citation: Gynecol Oncol. 2008 Jan;108(1):53-7
references.pmid: 17904208
references.citation: Gynecol Oncol. 2006 Aug;102(2):226-9
references.pmid: 16443259
references.citation: Int J Pharm. 2010 Apr 15;389(1-2):10-7
references.pmid: 20060458
references.citation: Gynecol Oncol. 2006 Jun;101(3):436-40
references.pmid: 16325893
references.citation: Gynecol Oncol. 2006 Feb;100(2):412-6
references.pmid: 16298422
references.citation: Oncology. 2001;60(1):19-23
references.pmid: 11150903
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2811-8
references.pmid: 17602086
references.citation: Gynecol Oncol. 2009 Oct;115(1):90-96
references.pmid: 19577796
references.citation: Gynecol Oncol. 2008 Jul;110(1):56-9
references.pmid: 18457865
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5
references.pmid: 15447993
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5180-6
references.pmid: 18024865
references.citation: Gynecol Oncol. 2006 Apr;101(1):126-31
references.pmid: 16271384
references.citation: Anticancer Res. 2007 May-Jun;27(3B):1645-51
references.pmid: 17595790
references.citation: Gynecol Oncol. 2009 Dec;115(3):396-400
references.pmid: 19804901
references.citation: Gynecol Oncol. 2008 Jan;108(1):47-52
references.pmid: 17915300
references.citation: Ann Oncol. 2000 Dec;11(12):1531-6
references.pmid: 11205459
references.citation: Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1717-32
references.pmid: 17009963
references.citation: Gynecol Oncol. 2005 Jan;96(1):67-71
references.pmid: 15589582
references.citation: Gynecol Oncol. 2006 Sep;102(3):468-74
references.pmid: 16516276
references.citation: Gynecol Oncol. 2008 Aug;110(2):146-51
references.pmid: 18538834
references.citation: J Natl Cancer Inst. 1992 Oct 7;84(19):1512-7
references.pmid: 1433335
references.citation: Ann Oncol. 2006 May;17 Suppl 5:v195-8
references.pmid: 16807455
references.citation: Clin Cancer Res. 2004 Nov 15;10(22):7439-49
references.pmid: 15569973
references.citation: Gynecol Oncol. 2007 Apr;105(1):132-7
references.pmid: 17161453
references.citation: Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1439-44
references.pmid: 387221
references.citation: Gynecol Oncol. 2007 Mar;104(3):647-53
references.pmid: 17079006
references.citation: Gynecol Oncol. 1990 Feb;36(2):207-11
references.pmid: 2404837
references.citation: Cancer. 2008 Aug 15;113(4):723-32
references.pmid: 18618737
references.citation: J Clin Oncol. 1991 Mar;9(3):389-93
references.pmid: 1999708
references.citation: Gynecol Oncol. 2003 Dec;91(3):573-6
references.pmid: 14675679
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Am J Clin Oncol. 2008 Oct;31(5):476-80
references.pmid: 18838885
references.citation: Gynecol Oncol. 2008 Dec;111(3):467-73
references.pmid: 18834619
references.citation: Gynecol Oncol. 2008 Jun;109(3):359-63
references.pmid: 18405948
references.citation: Acta Oncol. 2006;45(4):463-8
references.pmid: 16760183
references.citation: Int J Gynecol Cancer. 2007 Mar-Apr;17(2):359-66
references.pmid: 17362313
references.citation: Br J Cancer. 2005 Sep 19;93(6):647-51
references.pmid: 16222310
references.citation: Int J Clin Oncol. 2008 Apr;13(2):156-60
references.pmid: 18463961
references.citation: Nature. 2008 Feb 28;451(7182):1116-20
references.pmid: 18264087
references.citation: Gynecol Oncol. 2006 Jul;102(1):49-53
references.pmid: 16375951
references.citation: Int J Gynecol Cancer. 2005 Mar-Apr;15(2):209-16
references.pmid: 15823101
references.citation: Gynecol Oncol. 2006 Nov;103(2):446-50
references.pmid: 16643994
references.citation: Br J Cancer. 2007 Oct 8;97(7):927-33
references.pmid: 17848946
references.citation: Clin Transl Oncol. 2009 Jan;11(1):35-40
references.pmid: 19155202
references.citation: Eur J Cancer. 2009 Sep;45(13):2324-32
references.pmid: 19515553
references.citation: J Clin Oncol. 2007 Jul 10;25(20):2902-8
references.pmid: 17617521
references.citation: Br J Cancer. 1999 Jun;80(7):981-90
references.pmid: 10362105
references.citation: Gynecol Oncol. 2010 Jan;116(1):61-5
references.pmid: 19840886
references.citation: Gynecol Oncol. 2007 Aug;106(2):342-7
references.pmid: 17499346
references.citation: Int J Gynecol Cancer. 2007 Mar-Apr;17(2):373-8
references.pmid: 17362315
references.citation: Int J Oncol. 2006 Jan;28(1):237-44
references.pmid: 16328001